(BCPC) Balchem - Ratings and Ratios
Choline, Encapsulated Nutrients, Vitamin K2, Ethylene Oxide, Propylene Oxide
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.61% |
| Yield on Cost 5y | 0.84% |
| Yield CAGR 5y | 10.67% |
| Payout Consistency | 98.2% |
| Payout Ratio | 19.3% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 25.1% |
| Value at Risk 5%th | 38.1% |
| Relative Tail Risk | -7.53% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.12 |
| Alpha | -4.36 |
| CAGR/Max DD | 0.43 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.578 |
| Beta | 0.536 |
| Beta Downside | 0.502 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.10% |
| Mean DD | 8.60% |
| Median DD | 8.72% |
Description: BCPC Balchem January 08, 2026
Balchem Corporation (NASDAQ: BCPC) manufactures specialty performance ingredients for a broad set of markets-including human nutrition, animal health, and industrial sterilization-through three operating segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
The Human Nutrition & Health segment supplies spray-dried and emulsified powders, lipid systems, flavor delivery bases, and niche ingredients such as vitamin K2, microencapsulated nutrients, and choline compounds for food, beverage, and supplement applications. The Animal Nutrition & Health segment focuses on microencapsulated feed additives, chelated minerals, MSM, and choline chloride to improve health and milk production in ruminants and monogastric animals. The Specialty Products segment distributes ethylene oxide, ammonia, and propylene oxide for medical device sterilization and pest control, plus single-use canisters and chelated minerals for high-value crops.
Key metrics (FY 2023): revenue ≈ $2.1 billion, operating margin ≈ 12 %, and free cash flow of about $300 million, driven in part by rising demand for functional foods and protein-rich animal products. The specialty chemicals sector is sensitive to raw-material cost inflation and regulatory changes around sterilants, while long-term growth is supported by global trends toward healthier diets and increased food safety standards.
For a deeper dive into BCPC’s valuation metrics and peer comparison, see the ValueRay analysis.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 149.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -0.45 > 1.0 |
| NWC/Revenue: 21.44% < 20% (prev 22.98%; Δ -1.53% < -1%) |
| CFO/TA 0.12 > 3% & CFO 201.6m > Net Income 149.2m |
| Net Debt (106.9m) to EBITDA (260.1m): 0.41 < 3 |
| Current Ratio: 2.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.7m) vs 12m ago -0.25% < -2% |
| Gross Margin: 35.82% > 18% (prev 0.34%; Δ 3548 % > 0.5%) |
| Asset Turnover: 62.22% > 50% (prev 59.01%; Δ 3.21% > 0%) |
| Interest Coverage Ratio: 18.82 > 6 (EBITDA TTM 260.1m / Interest Expense TTM 10.9m) |
Altman Z'' (< 1.1 .. > 2.6) 7.23
| A: 0.13 (Total Current Assets 343.7m - Total Current Liabilities 126.4m) / Total Assets 1.66b |
| B: 0.67 (Retained Earnings 1.11b / Total Assets 1.66b) |
| C: 0.13 (EBIT TTM 204.3m / Avg Total Assets 1.63b) |
| D: 3.19 (Book Value of Equity 1.16b / Total Liabilities 363.2m) |
| Altman-Z'' Score: 7.23 = AAA |
ValueRay F-Score (Strict, 0-100) 73.52
| 1. Piotroski: 8.0pt |
| 2. FCF Yield: 2.89% |
| 3. FCF Margin: 15.94% |
| 4. Debt/Equity: 0.13 |
| 5. Debt/Ebitda: 0.41 |
| 6. ROIC - WACC: 3.52% |
| 7. RoE: 12.12% |
| 8. Revenue Trend: 75.96% |
| 9. EPS Trend: -17.65% |
What is the price of BCPC shares?
Over the past week, the price has changed by +5.59%, over one month by +8.27%, over three months by +8.35% and over the past year by +4.27%.
Is BCPC a buy, sell or hold?
- Strong Buy: 0
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BCPC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 191 | 13.1% |
| Analysts Target Price | 191 | 13.1% |
| ValueRay Target Price | 177.9 | 5.3% |
BCPC Fundamental Data Overview January 21, 2026
P/E Forward = 32.6797
P/S = 5.4033
P/B = 4.2107
P/EG = 4.8341
Revenue TTM = 1.01b USD
EBIT TTM = 204.3m USD
EBITDA TTM = 260.1m USD
Long Term Debt = 154.0m USD (from longTermDebt, last quarter)
Short Term Debt = 4.14m USD (from shortTermDebt, last quarter)
Debt = 172.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 106.9m USD (from netDebt column, last quarter)
Enterprise Value = 5.58b USD (5.48b + Debt 172.0m - CCE 65.1m)
Interest Coverage Ratio = 18.82 (Ebit TTM 204.3m / Interest Expense TTM 10.9m)
EV/FCF = 34.55x (Enterprise Value 5.58b / FCF TTM 161.6m)
FCF Yield = 2.89% (FCF TTM 161.6m / Enterprise Value 5.58b)
FCF Margin = 15.94% (FCF TTM 161.6m / Revenue TTM 1.01b)
Net Margin = 14.72% (Net Income TTM 149.2m / Revenue TTM 1.01b)
Gross Margin = 35.82% ((Revenue TTM 1.01b - Cost of Revenue TTM 650.5m) / Revenue TTM)
Gross Margin QoQ = 35.68% (prev 36.45%)
Tobins Q-Ratio = 3.36 (Enterprise Value 5.58b / Total Assets 1.66b)
Interest Expense / Debt = 1.37% (Interest Expense 2.35m / Debt 172.0m)
Taxrate = 22.59% (11.8m / 52.0m)
NOPAT = 158.2m (EBIT 204.3m * (1 - 22.59%))
Current Ratio = 2.72 (Total Current Assets 343.7m / Total Current Liabilities 126.4m)
Debt / Equity = 0.13 (Debt 172.0m / totalStockholderEquity, last quarter 1.30b)
Debt / EBITDA = 0.41 (Net Debt 106.9m / EBITDA 260.1m)
Debt / FCF = 0.66 (Net Debt 106.9m / FCF TTM 161.6m)
Total Stockholder Equity = 1.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.16% (Net Income 149.2m / Total Assets 1.66b)
RoE = 12.12% (Net Income TTM 149.2m / Total Stockholder Equity 1.23b)
RoCE = 14.75% (EBIT 204.3m / Capital Employed (Equity 1.23b + L.T.Debt 154.0m))
RoIC = 11.20% (NOPAT 158.2m / Invested Capital 1.41b)
WACC = 7.68% (E(5.48b)/V(5.65b) * Re(7.89%) + D(172.0m)/V(5.65b) * Rd(1.37%) * (1-Tc(0.23)))
Discount Rate = 7.89% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.35%
[DCF Debug] Terminal Value 81.68% ; FCFF base≈162.0m ; Y1≈190.6m ; Y5≈291.0m
Fair Price DCF = 160.2 (EV 5.30b - Net Debt 106.9m = Equity 5.19b / Shares 32.4m; r=7.68% [WACC]; 5y FCF grow 18.81% → 2.90% )
EPS Correlation: -17.65 | EPS CAGR: -46.99% | SUE: -4.0 | # QB: 0
Revenue Correlation: 75.96 | Revenue CAGR: 6.25% | SUE: 1.65 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.31 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=5.57 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+9.0% | Growth Revenue=+6.4%
Additional Sources for BCPC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle